A citation-based method for searching scientific literature

Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein, Alexander Bausch, George Garibaldi, Luca Santarelli. JAMA Psychiatry 2014
Times Cited: 138







List of co-cited articles
1368 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
Daniela Alberati, Jean-Luc Moreau, Judith Lengyel, Nicole Hauser, Roland Mory, Edilio Borroni, Emmanuel Pinard, Frederic Knoflach, Götz Schlotterbeck, Dominik Hainzl,[...]. Neuropharmacology 2012
90
27

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
25

D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
505
22


Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
259
21

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
21

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Hsien-Yuan Lane, Ching-Hua Lin, Michael F Green, Gerhard Hellemann, Chih-Chia Huang, Po-Wei Chen, Rene Tun, Yue-Cung Chang, Guochuan E Tsai. JAMA Psychiatry 2013
134
20

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
293
20

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
787
19

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Hsien-Yuan Lane, Yue-Cune Chang, Yi-Ching Liu, Chih-Chiang Chiu, Guochuan E Tsai. Arch Gen Psychiatry 2005
209
18

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
Dragana Bugarski-Kirola, Thomas Blaettler, Celso Arango, Wolfgang W Fleischhacker, George Garibaldi, Alice Wang, Mark Dixon, Rodrigo A Bressan, Henry Nasrallah, Stephen Lawrie,[...]. Biol Psychiatry 2017
47
38

The positive and negative syndrome scale (PANSS) for schizophrenia.
S R Kay, A Fiszbein, L A Opler. Schizophr Bull 1987
17

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, G Silipo, M Lichtenstein. Arch Gen Psychiatry 1999
356
17


A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Mark Weiser, Uriel Heresco-Levy, Michael Davidson, Daniel C Javitt, Nomi Werbeloff, Ari A Gershon, Yehuda Abramovich, Daniela Amital, Adiel Doron, Shai Konas,[...]. J Clin Psychiatry 2012
67
23

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Hsien-Yuan Lane, Ching-Hua Lin, Yu-Jhen Huang, Chun-Hui Liao, Yue-Cune Chang, Guochuan E Tsai. Int J Neuropsychopharmacol 2010
125
16

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Pesah Lichtenberg, Gali Bar, Daniel C Javitt. Biol Psychiatry 2004
173
16

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, A Horowitz, D Kelly. Br J Psychiatry 1996
198
16



Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
76
19

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
267
15

High dose D-serine in the treatment of schizophrenia.
Joshua T Kantrowitz, Anil K Malhotra, Barbara Cornblatt, Gail Silipo, Andrea Balla, Raymond F Suckow, Cyril D'Souza, John Saksa, Scott W Woods, Daniel C Javitt. Schizophr Res 2010
158
14



D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
Joshua T Kantrowitz, Scott W Woods, Eva Petkova, Barbara Cornblatt, Cheryl M Corcoran, Huaihou Chen, Gail Silipo, Daniel C Javitt. Lancet Psychiatry 2015
91
14

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Chun-Yuan Lin, Sun-Yuan Liang, Yue-Cune Chang, Shuo-Yen Ting, Ching-Ling Kao, Yu-Hsin Wu, Guochuan E Tsai, Hsien-Yuan Lane. World J Biol Psychiatry 2017
50
26

The NIMH-MATRICS consensus statement on negative symptoms.
Brian Kirkpatrick, Wayne S Fenton, William T Carpenter, Stephen R Marder. Schizophr Bull 2006
780
13

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Hsien-Yuan Lane, Yi-Ching Liu, Chieh-Liang Huang, Yue-Cune Chang, Chun-Hui Liau, Cheng-Hwang Perng, Guochuan E Tsai. Biol Psychiatry 2008
116
12



Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Philipp Singer, Sylvain Dubroqua, Benjamin K Yee. Curr Pharm Des 2015
24
50

Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.
A C Lahti, B Koffel, D LaPorte, C A Tamminga. Neuropsychopharmacology 1995
648
12

Amelioration of negative symptoms in schizophrenia by glycine.
D C Javitt, I Zylberman, S R Zukin, U Heresco-Levy, J P Lindenmayer. Am J Psychiatry 1994
286
12


Modulation of N-methyl-D-aspartate receptor function by glycine transport.
R Bergeron, T M Meyer, J T Coyle, R W Greene. Proc Natl Acad Sci U S A 1998
341
11

Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.
Thomas Papouin, Laurent Ladépêche, Jérôme Ruel, Silvia Sacchi, Marilyne Labasque, Marwa Hanini, Laurent Groc, Loredano Pollegioni, Jean-Pierre Mothet, Stéphane H R Oliet. Cell 2012
447
11

Adjunctive high-dose glycine in the treatment of schizophrenia.
D C Javitt, G Silipo, A Cienfuegos, A M Shelley, N Bark, M Park, J P Lindenmayer, R Suckow, S R Zukin. Int J Neuropsychopharmacol 2001
122
11

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
John E Lisman, Joseph T Coyle, Robert W Green, Daniel C Javitt, Francine M Benes, Stephan Heckers, Anthony A Grace. Trends Neurosci 2008
715
11

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Joshua T Kantrowitz, Michael L Epstein, Migyung Lee, Nayla Lehrfeld, Karen A Nolan, Constance Shope, Eva Petkova, Gail Silipo, Daniel C Javitt. Schizophr Res 2018
53
20

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
176
10

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
D C Goff, G Tsai, J Levitt, E Amico, D Manoach, D A Schoenfeld, D L Hayden, R McCarley, J T Coyle. Arch Gen Psychiatry 1999
308
10

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Hsien-Yuan Lane, Chieh-Liang Huang, Po-Lun Wu, Yi-Ching Liu, Yue-Cune Chang, Pao-Yen Lin, Po-Wei Chen, Guochuan Tsai. Biol Psychiatry 2006
117
10

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Donald C Goff, Corinne Cather, Jennifer D Gottlieb, A Eden Evins, Jared Walsh, Lisa Raeke, Michael W Otto, David Schoenfeld, Michael F Green. Schizophr Res 2008
94
10

Glycine binding primes NMDA receptor internalization.
Yi Nong, Yue-Qiao Huang, William Ju, Lorraine V Kalia, Gholamreza Ahmadian, Yu Tian Wang, Michael W Salter. Nature 2003
321
10

d-Cycloserine augmentation of cognitive remediation in schizophrenia.
Christopher K Cain, Margaret McCue, Iruma Bello, Timothy Creedon, Dei-In Tang, Eugene Laska, Donald C Goff. Schizophr Res 2014
52
19

Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Chih-Chia Huang, I-Hua Wei, Chieh-Liang Huang, Kuang-Ti Chen, Mang-Hung Tsai, Priscilla Tsai, Rene Tun, Kuo-Hao Huang, Yue-Cune Chang, Hsien-Yuan Lane,[...]. Biol Psychiatry 2013
90
11


Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
Dominik Strzelecki, Michał Podgórski, Olga Kałużyńska, Oliwia Gawlik-Kotelnicka, Ludomir Stefańczyk, Magdalena Kotlicka-Antczak, Agnieszka Gmitrowicz, Piotr Grzelak. Neurosci Lett 2015
18
55

Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
Eduardo Dunayevich, Robert W Buchanan, Chao-Yin Chen, Jun Yang, Jon Nilsen, Julie M Dietrich, Hong Sun, Stephen Marder. Schizophr Res 2017
18
55


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.